299 related articles for article (PubMed ID: 35673559)
1. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
Shi R; Wang X; Wu Y; Xu B; Zhao T; Trapp C; Wang X; Unger K; Zhou C; Lu S; Buchner A; Schulz GB; Cao F; Belka C; Su C; Li M; Shu Y
Theranostics; 2022; 12(9):4181-4199. PubMed ID: 35673559
[No Abstract] [Full Text] [Related]
2. Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma.
Yang J; Xiang T; Zhu S; Lao Y; Wang Y; Liu T; Li K; Ma Y; Zhong C; Zhang S; Tan W; Lin D; Wu C
Int J Biol Sci; 2023; 19(8):2551-2571. PubMed ID: 37215984
[TBL] [Abstract][Full Text] [Related]
3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
4. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
5. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.
Roberts SA; Lawrence MS; Klimczak LJ; Grimm SA; Fargo D; Stojanov P; Kiezun A; Kryukov GV; Carter SL; Saksena G; Harris S; Shah RR; Resnick MA; Getz G; Gordenin DA
Nat Genet; 2013 Sep; 45(9):970-6. PubMed ID: 23852170
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
7. APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
Vile RG; Melcher A; Pandha H; Harrington KJ; Pulido JS
Clin Cancer Res; 2021 Jun; 27(12):3280-3290. PubMed ID: 33558423
[TBL] [Abstract][Full Text] [Related]
8. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
9. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
10. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
11. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
12. APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer.
Guo H; Zhu L; Huang L; Sun Z; Zhang H; Nong B; Xiong Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740493
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy.
Xiao Y; Dong Y; Yu T; Wang R; Gao Y; Li S; Nong S; Li W
Front Immunol; 2022; 13():941189. PubMed ID: 36091015
[TBL] [Abstract][Full Text] [Related]
14.
Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
16. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
17. Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
Wang T; Ding G; Wang X; Cui Y; Ma X; Ma J; Wu J
Arch Med Res; 2024 Jan; 55(1):102927. PubMed ID: 38154234
[TBL] [Abstract][Full Text] [Related]
18. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
[TBL] [Abstract][Full Text] [Related]
19. APOBEC: From mutator to editor.
Yang B; Li X; Lei L; Chen J
J Genet Genomics; 2017 Sep; 44(9):423-437. PubMed ID: 28964683
[TBL] [Abstract][Full Text] [Related]
20. Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
Chen S; Ran J; Fan Z; Liu M; Wu L; Li Q; Peng J; Hu Z
Sci Rep; 2023 Aug; 13(1):12625. PubMed ID: 37537337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
